Literature DB >> 6692285

Soft tissue sarcoma of the head and neck in childhood: nonorbital and nonparameningeal sites. A report of the Intergroup Rhabdomyosarcoma Study (IRS)-I.

M D Wharam, M A Foulkes, W Lawrence, R D Lindberg, H M Maurer, W A Newton, A H Ragab, R B Raney, M Tefft.   

Abstract

Seventy-two patients with soft tissue sarcoma arising in the oral cavity, oropharynx, larynx, parotid region, cheek, scalp, and neck, were entered on the Intergroup Rhabdomyosarcoma Study (IRS)-I, and could be analyzed for survival. Sixty-three (88%) attained complete remission (CR), of whom 13 subsequently relapsed (78% actuarial 5-year retained CR rate). The patients with primary tumor arising in sites other than the neck had a retained CR rate exceeding 90%. In contrast, 11 relapses occurred in the 26 patients with neck primaries (54% retained CR rate). Females, and infants younger than age 24 months were more likely to relapse. Prognostic factors with little or no influence on relapse included tumor size, histology, regional lymph node status, clinical group, and treatment arm. Five of the 6 patients with failure at the primary site had either no radiotherapy (2 patients) or an insufficient dose (less than 3000 rad). No patient required major organ sacrifice such as laryngectomy or pharyngectomy. Isolated failure in regional nodes did not occur. Children with nonorbital, nonparameningeal head and neck soft tissue sarcoma treated in accordance with the IRS protocol have an excellent rate of local control and survival. Primary tumors arising in the neck are more likely to relapse locally or distantly.

Entities:  

Mesh:

Year:  1984        PMID: 6692285     DOI: 10.1002/1097-0142(19840215)53:4<1016::aid-cncr2820530432>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Management of sarcomas of the head and neck.

Authors:  Bruce Brockstein
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

2.  Histiocytosis X of the petrous bone in the adult: MRI.

Authors:  A Bonafé; H Joomye; P Jaeger; B Fraysse; C Manelfe
Journal:  Neuroradiology       Date:  1994-05       Impact factor: 2.804

3.  Rhabdomyosarcoma: a rare laryngeal neoplastic entity.

Authors:  B Pittore; G Fancello; P Cossu Rocca; G P Ledda; G Tore
Journal:  Acta Otorhinolaryngol Ital       Date:  2010-02       Impact factor: 2.124

4.  Local therapy of rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma of children and adolescents.

Authors:  G Prindull; H G Willert; G Notter
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

5.  Rhabdomyosarcoma of parotid gland.

Authors:  A Goel; S C Gupta; S C Gupta; D N Awasthi
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1997-10

6.  Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997.

Authors:  R Beverly Raney; Murali Chintagumpala; James Anderson; Alberto Pappo; Stephen Qualman; Moody Wharam; Eugene Wiener; William Meyer
Journal:  Pediatr Blood Cancer       Date:  2008-05       Impact factor: 3.167

7.  Adult rhabdomyosarcoma originating in the temporal muscle, invading the skull and meninges: A case report.

Authors:  Geng-Huan Wang; He-Ping Shen; Zheng-Min Chu; Jian Shen
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

8.  Head and neck sarcomas: prognostic factors and implications for treatment.

Authors:  R A Eeles; C Fisher; R P A'Hern; M Robinson; P Rhys-Evans; J M Henk; D Archer; C L Harmer
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.